Acurx Pharmaceuticals (ACXP) Operating Expenses (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Operating Expenses came in at $1.7 million in Q1 2026, down 21.16% YoY from $2.2 million in Q1 2025, and up 6.11% on a QoQ basis from $1.6 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Operating Expenses (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Operating Expenses data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Operating Expenses fell 21.16% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 35.97% YoY) and the FY2025 annual result came in at $8.1 million, down 42.7% from the prior year.
- Operating Expenses climbed to $1.7 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $5.1 million in Q4 2023 to a low of $1.6 million in Q4 2025.
- A 5-year average of $3.0 million and a median of $2.8 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 81.11% — and 2025, when it sank 50.28%.
- Tracing ACXP's Operating Expenses over 5 years: stood at $3.3 million in 2022, then jumped by 56.86% to $5.1 million in 2023, then slumped by 45.38% to $2.8 million in 2024, then plunged by 42.12% to $1.6 million in 2025, then rose by 6.11% to $1.7 million in 2026.
- The last three Operating Expenses figures came in at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.31 Mn |
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 2.03 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 2.18 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 4.12 Mn |
| Mar 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 5.11 Mn |
| Sep 30, 2023 | 3.11 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | 2.90 Mn |
| Dec 31, 2022 | 3.26 Mn |
| Sep 30, 2022 | 3.54 Mn |
| Jun 30, 2022 | 2.62 Mn |
| Mar 31, 2022 | 2.67 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Sep 30, 2021 | 4.64 Mn |